Robert Ryan
Non-Executive Director
Board of Directors
Factor Therapeutics
Australia
Biography
Dr. Ryan has more than 27 years of research/pharmaceutical/biotech experience, spanning the global development process from preclinical through Phase IV, and covering senior preclinical, regulatory and clinical activities with Roche, Bristol-Myers Squibb (BMS), UCB, Atherogenics, and Pfizer. Dr. Ryan is currently the President and CEO of Innova Therapeutics, a company focused on developing innovative therapies for diseases with high unmet needs. Prior to Innova, Dr. Ryan was the President and CEO of Scioderm, where he led the development of SD-101, a topical therapy for Epidermolysis Bullosa. Scioderm was the first biotech to receive “Breakthrough Therapy” designation from the FDA, and the company was sold in 2015 to Amicus Therapeutics, with upfront payments and milestones totaling approximately $957 million. Dr Ryan has direct product development experience that has resulted in the approval of over 20 drug candidates in various therapeutic areas. Dr. Ryan graduated with a doctorate degree in Toxicology from the University of North Carolina at Chapel Hill, MS degrees in Pharmacokinetics and Genetics, and is a Diplomate of the American Board of Toxicology.
Research Interest
Business
